Luspatercept
Reblozyl
Near Add Your Location
Accepting patients
ELEMENT-MDS
Phase 3 Clinical Trial Comparing Luspatercept VS Epoetin Alfa in Patients with Very Low – Intermediate Risk MDS Who Are Not Transfusion Dependent
- Erythroid Maturation Agent (EMA)
- Erythropoiesis-Stimulating Agent (ESA)
- Red Blood Cell Stimulant
- Phase 3
Accepting patients
A Phase 2, Single Arm Study of Luspatercept for the Treatment of Anemia in Lower Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Myelodysplastic Syndromes/ Myeloproliferative Neoplasms (MDS/MPN)
- Erythroid Maturation Agent (EMA)
- Red Blood Cell Stimulant
- Phase 2
Accepting patients
Luspatercept for Lower Risk MDS
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
- Erythroid Maturation Agent (EMA)
- Red Blood Cell Stimulant
- Growth Factor
- Phase 2
Accepting patients
Luspatercept and Lenalidomide (L2)
A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients
- Erythroid Maturation Agent (EMA)
- Immunomodulatory Drug
- Red Blood Cell Stimulant
- Phase 1/2